eprintid: 10109467
rev_number: 17
eprint_status: archive
userid: 608
dir: disk0/10/10/94/67
datestamp: 2020-09-09 16:31:37
lastmod: 2021-09-17 22:22:46
status_changed: 2020-09-09 16:31:37
type: article
metadata_visibility: show
creators_name: Benussi, A
creators_name: Ashton, NJ
creators_name: Karikari, TK
creators_name: Gazzina, S
creators_name: Premi, E
creators_name: Benussi, L
creators_name: Ghidoni, R
creators_name: Rodriguez, JL
creators_name: Emeršič, A
creators_name: Binetti, G
creators_name: Fostinelli, S
creators_name: Giunta, M
creators_name: Gasparotti, R
creators_name: Zetterberg, H
creators_name: Blennow, K
creators_name: Borroni, B
title: Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration
ispublished: inpress
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F86
keywords: Biomarker, frontotemporal dementia, glial fibrillary acidic protein, magnetic resonance imaging, serum, survival, transcranial magnetic stimulation
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
abstract: BACKGROUND: It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD). OBJECTIVE: To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD. METHODS: In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer's disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival. RESULTS: We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with AD patients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival. CONCLUSION: Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.
date: 2020-08-14
date_type: published
official_url: https://doi.org/10.3233/JAD-200608
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1808897
doi: 10.3233/JAD-200608
pii: JAD200608
lyricists_name: Zetterberg, Henrik
lyricists_id: HZETT94
actors_name: Zetterberg, Henrik
actors_name: Harriot, Anne-Marie
actors_id: HZETT94
actors_id: AHARA72
actors_role: owner
actors_role: impersonator
full_text_status: public
publication: Journal of Alzheimer's Disease
event_location: Netherlands
citation:        Benussi, A;    Ashton, NJ;    Karikari, TK;    Gazzina, S;    Premi, E;    Benussi, L;    Ghidoni, R;                                     ... Borroni, B; + view all <#>        Benussi, A;  Ashton, NJ;  Karikari, TK;  Gazzina, S;  Premi, E;  Benussi, L;  Ghidoni, R;  Rodriguez, JL;  Emeršič, A;  Binetti, G;  Fostinelli, S;  Giunta, M;  Gasparotti, R;  Zetterberg, H;  Blennow, K;  Borroni, B;   - view fewer <#>    (2020)    Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration.                   Journal of Alzheimer's Disease        10.3233/JAD-200608 <https://doi.org/10.3233/JAD-200608>.    (In press).    Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10109467/3/Zetterberg_Serum%20Glial%20Fibrillary%20Acidic%20Protein%20%28GFAP%29%20Is%20a%20Marker%20of%20Disease%20Severity%20in%20Frontotemporal%20Lobar%20Degeneration_AAM.pdf